WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H208096
CAS#: 2631703-41-6
Description: ENPP1 inhibitor 43 is a novel small molecule for cancer immunotherapy.
Hodoodo Cat#: H208096
Name: ENPP1 inhibitor 43
CAS#: 2631703-41-6
Chemical Formula: C16H18N6O3S
Exact Mass: 374.12
Molecular Weight: 374.420
Elemental Analysis: C, 51.33; H, 4.85; N, 22.45; O, 12.82; S, 8.56
Synonym: ENPP1 inhibitor 43; ENPP1 inhibitor 43
IUPAC/Chemical Name: 2-((2-amino-7H-purin-6-yl)thio)-N-(4-hydroxy-3-methoxyphenyl)butanamide
InChi Key: ZDCMJGUVFRHQEH-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H18N6O3S/c1-3-11(14(24)20-8-4-5-9(23)10(6-8)25-2)26-15-12-13(19-7-18-12)21-16(17)22-15/h4-7,11,23H,3H2,1-2H3,(H,20,24)(H3,17,18,19,21,22)
SMILES Code: COC1=CC(NC(C(CC)SC2=NC(N)=NC3=C2NC=N3)=O)=CC=C1O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 374.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Gangar M, Goyal S, Raykar D, Khurana P, Martis AM, Goswami A, Ghoshal I, Patel KV, Nagare Y, Raikar S, Mukherjee A, Cyriac R, Paquin JF, Kulkarni A. Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy. Bioorg Chem. 2022 Feb;119:105549. doi: 10.1016/j.bioorg.2021.105549. Epub 2021 Dec 11. PMID: 34929517.
2. Marucci A, Antonucci A, De Bonis C, Mangiacotti D, Scarale MG, Trischitta V, Di Paola R. GALNT2 as a novel modulator of adipogenesis and adipocyte insulin signaling. Int J Obes (Lond). 2019 Dec;43(12):2448-2457. doi: 10.1038/s41366-019-0367-3. Epub 2019 Apr 30. PMID: 31040393.
3. Villa-Bellosta R, González-Parra E, Egido J. Alkalosis and Dialytic Clearance of Phosphate Increases Phosphatase Activity: A Hidden Consequence of Hemodialysis. PLoS One. 2016 Jul 25;11(7):e0159858. doi: 10.1371/journal.pone.0159858. PMID: 27454315; PMCID: PMC4959680.
4. Weedon MN, Shields B, Hitman G, Walker M, McCarthy MI, Hattersley AT, Frayling TM. No evidence of association of ENPP1 variants with type 2 diabetes or obesity in a study of 8,089 U.K. Caucasians. Diabetes. 2006 Nov;55(11):3175-9. doi: 10.2337/db06-0410. PMID: 17065358.